SavedAdd your journal

Journals / Eurasian Journal of Emergency Medicine / 2022 / Cilt: 21 - Sayı: 1

Management of Arrhythmias in COVID-19

Yusuf Ziya ŞENER
Hikmet YORGAN
Uğur CANPOLAT
Kudret AYTEMİR
Pages
1–7
Publication Date
2022-10-11
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

All the clinicians should know the management of arrhythmias that they might face with frequently during the pandemic.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Coronavirus disease-2019 (COVID-19) disease is caused by severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) virus infection and firstly appeared in China and then became a pandemic.
📊
Key Findings & Data:The leading cause of mortality is respiratory failure in COVID-19; however, cardiovascular manifestations are frequent and also important causes of death in COVID-19.
💡
Conclusion & Impact:All the clinicians should know the management of arrhythmias that they might face with frequently during the pandemic.
🔬Design:Research Article
📍Scope:2019 Verileri
⚙️Variables:Domain Parameters

Abstract

Coronavirus disease-2019 (COVID-19) disease is caused by severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) virus infection and firstly appeared in China and then became a pandemic. The leading cause of mortality is respiratory failure in COVID-19; however, cardiovascular manifestations are frequent and also important causes of death in COVID-19. The incidence of arrhythmia is increased in patients with COVID-19 due to increased systemic inflammatory response, hypoxia, and administered drugs. All kinds of arrhythmias, including bradyarrhythmias, supraventricular and ventricular arrhythmias, may develop during COVID-19 course. QT prolongation plays a central role in COVID-19 related arrhythmias. Therefore, QT duration should be strictly followed. All the clinicians should know the management of arrhythmias that they might face with frequently during the pandemic.

🔖

Cite This Article

ŞENER, Y. Z., YORGAN, H., CANPOLAT, U., AYTEMİR, K. (2022). Management of Arrhythmias in COVID-19. Eurasian Journal of Emergency Medicine, Cilt: 21 - Sayı: 1, 1–7. https://ajindex.com/articles/507899

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Lazzerini PE, Boutjdir M, Capecchi PL. COVID-19, Arrhythmic risk, and inflammation: mind The gap! Circulation. 2020;142:7-9
  2. Driggin E, Madhavan MV, Bikdeli B, Chuich T, Laracy J, Biondi-Zoccai G, et al. Cardiovascular considerations for patients, health care workers, and health systems during the coronavirus disease 2019 (COVID-19) pandemic. J Am Coll Cardiol. 2020;75:2352-71
  3. Si D, Du B, Ni L, Yang B, Sun H, Jiang N, et al. Death, discharge, and arrhythmias among patients with COVID-19 and cardiac injury. CMAJ. 2020;cmaj.200879
  4. Bhatla A, Mayer MM, Adusumalli S, Lin D, Marchlinski F, Deo R, et al. COVID-19 and Cardiac Arrhythmias. Heart Rhythm. 2020;S1547-5271:30594-4
  5. Lazzerini PE, Laghi-Pasini F, Boutjdir M, Capecchi PL. Cardioimmunology of arrhythmias: the role of autoimmune and inflammatory cardiac channelopathies. Nat Rev Immunol. 2019;19:63-4
  6. Colon CM, Barrios JG, Chiles JW, McElwee SK, Russell DW, Maddox WR, et al. Atrial arrhythmias in COVID-19 patients. JACC Clin Electrophysiol. 2020;6:1189-90
  7. The European Society for Cardiology. ESC Guidance for the Diagnosis and Management of CV Disease during the COVID-19 Pandemic. Available from: https://www.escardio.org/The-ESC/Press-Office/Press-releases/ESC-Guidancefor-the-Diagnosis-and-Management-of-Heart-Disease-during-COVID- 19 8. Duchin K, Duggal A, Atiee GJ, Kidokoro M, Takatani T, Shipitofsky NL, et al. An open-label crossover study of the pharmacokinetics of the 60-mg edoxaban tablet crushed and administered either by a nasogastric tube or in apple puree in healthy adults. Clin Pharmacokinet. 2018;57:221-8
  8. Song Y, Wang X, Perlstein I, Wang J, Badawy S, Frost C, et al. Relative Bioavailability of Apixaban Solution or Crushed Tablet Formulations Administered by Mouth or Nasogastric Tube in Healthy Subjects. Clin Ther. 2015;37:1703-12
  9. Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020;5:811-8
  10. Song MK, Bae EJ, Baek JS, Kwon BS, Kim GB, Noh CI, et al. QT prolongation and life threatening ventricular tachycardia in a patient injected with intravenous meperidine (Demerol®). Korean Circ J. 2011;41:342-5
  11. Viskin S. The QT interval: too long, too short or just right. Heart Rhythm. 2009;6:711-5
  12. Chakravarty S, Kluger J, Chhabra L, Ramu B, Coleman C. Corrected QT in ventricular paced rhythms: what is the validation for commonly practiced assumptions?